HLVX insider transaction filings
HilleVax, Inc. — 43 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-09-19. Screen HLVX transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for HLVX between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — HilleVax, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-09-19 | 4 | TAKEDA PHARMACEUTICAL CO LTD — 10% owner Takeda Vaccines, Inc. — 10% owner | Code (U): 6,724,000 @ $1.95 | EDGAR |
| 2025-09-17 | 4 | Sepulveda Jaime — Director | Code (U): 59,224 | EDGAR |
| 2025-09-17 | 4 | Cocero Nanette — Director | Code (U): 17,199 | EDGAR |
| 2025-09-17 | 4 | Chu Shelley — Director | Code (U): 17,199 | EDGAR |
| 2025-09-17 | 4 | Dubin Gary — Director | Code (U): 17,199 | EDGAR |
| 2025-09-17 | 4 | Kohli Aditya — Director | Code (U): 698,171 | EDGAR |
| 2025-09-17 | 4 | Maltbie Shane — Chief Financial Officer | Code (U): 83,738 | EDGAR |
| 2025-09-17 | 4 | Gerberding Julie L. — Director | Code (U): 59,224 | EDGAR |
| 2025-09-17 | 4 | Frazier Life Sciences X, L.P. — 10% owner FHMLS X, L.P. — 10% owner FHMLS X, L.L.C. — 10% owner Topper James N — 10% owner Heron Patrick J — Director, 10% owner | Code (U): 8,535,337 @ $1.95 · Code (U): 17,199 @ $1.95 | EDGAR |
| 2025-09-17 | 4 | HERSHBERG ROBERT — President and CEO, Director | Code (U): 1,101,498 | EDGAR |
| 2025-09-17 | 4 | HILLEMAN JERYL L — Director | Code (U): 59,224 | EDGAR |
| 2025-06-25 | 4 | Chu Shelley — Director | Grant/award (A): 17,199 @ $0 | EDGAR |
| 2025-06-25 | 4 | Sepulveda Jaime — Director | Grant/award (A): 17,199 @ $0 | EDGAR |
| 2025-06-25 | 4 | Cocero Nanette — Director | Grant/award (A): 17,199 @ $0 | EDGAR |
| 2025-06-25 | 4 | Dubin Gary — Director | Grant/award (A): 17,199 @ $0 | EDGAR |
| 2025-06-25 | 4 | Kohli Aditya — Director | Grant/award (A): 17,199 @ $0 | EDGAR |
| 2025-06-25 | 4 | Gerberding Julie L. — Director | Grant/award (A): 17,199 @ $0 | EDGAR |
| 2025-06-25 | 4 | Heron Patrick J — Director | Grant/award (A): 17,199 @ $0 | EDGAR |
| 2025-06-25 | 4 | HILLEMAN JERYL L — Director | Grant/award (A): 17,199 @ $0 | EDGAR |
| 2025-04-30 | 4 | Chu Shelley — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-04-30 | 4 | Cocero Nanette — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-04-30 | 4 | Sepulveda Jaime — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-04-30 | 4 | Gerberding Julie L. — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-04-30 | 4 | Heron Patrick J — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-04-30 | 4 | HILLEMAN JERYL L — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-02-12 | 4 | Maltbie Shane — Chief Financial Officer | Sale (S): 3,946 @ $1.89 · Sale (S): 4,345 @ $1.76 | EDGAR |
| 2025-02-12 | 4 | HERSHBERG ROBERT — See Remarks, Director | Sale (S): 14,634 @ $1.89 · Sale (S): 11,901 @ $1.76 | EDGAR |
| 2024-05-31 | 4/A | Frazier Life Sciences X, L.P. — 10% owner FHMLS X, L.P. — 10% owner FHMLS X, L.L.C. — 10% owner Topper James N — 10% owner Heron Patrick J — Director, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2024-05-22 | 4 | Kohli Aditya — Director | Sale (S): 6,000 @ $15.45 · Sale (S): 6,000 @ $14.21 · Sale (S): 6,000 @ $14.73 | EDGAR |
| 2024-05-03 | 4 | Kohli Aditya — Director | Sale (S): 175 @ $14.03 · Sale (S): 6,000 @ $14.01 · Sale (S): 723 @ $14.15 | EDGAR |
| 2024-04-08 | 4 | Frazier Life Sciences X, L.P. — 10% owner FHMLS X, L.P. — 10% owner FHMLS X, L.L.C. — 10% owner Topper James N — 10% owner Heron Patrick J — Director, 10% owner | Purchase (P): 8,850 @ $14.50 | EDGAR |
| 2024-04-05 | 4 | Kohli Aditya — Director | Sale (S): 6,000 @ $14.93 · Sale (S): 6,000 @ $14.71 · Sale (S): 6,000 @ $14.44 | EDGAR |
| 2024-04-01 | 4 | McLoughlin Sean — Chief Operating Officer | Purchase (P): 1,250 @ $16.98 | EDGAR |
| 2024-03-20 | 4 | Kohli Aditya — Director | Sale (S): 6,000 @ $17.66 · Sale (S): 6,000 @ $17.42 · Sale (S): 6,000 @ $164,221 | EDGAR |
| 2024-03-08 | 4 | Kohli Aditya — Director | Sale (S): 6,000 @ $18.95 · Sale (S): 6,000 @ $18.37 · Sale (S): 6,000 @ $18.66 | EDGAR |
| 2024-02-22 | 4 | Kohli Aditya — Director | Sale (S): 6,000 @ $14.88 · Sale (S): 6,000 @ $14.92 · Sale (S): 6,000 @ $15.05 | EDGAR |
| 2024-02-14 | 4 | Kohli Aditya — Director | Sale (S): 6,000 @ $15.32 | EDGAR |
| 2024-02-12 | 4 | Borkowski Astrid — Chief Medical Officer | Sale (S): 3,933 @ $14.93 · Grant/award (A): 53,632 @ $0 · Grant/award (A): 69,852 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | Kohli Aditya — Director | Sale (S): 8,866 @ $14.93 · Grant/award (A): 54,898 @ $0 · Grant/award (A): 71,500 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | Maltbie Shane — Chief Financial Officer | Sale (S): 3,576 @ $14.93 · Grant/award (A): 47,522 @ $0 · Grant/award (A): 61,894 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | HERSHBERG ROBERT — See Remarks, Director | Sale (S): 11,597 @ $14.93 · Grant/award (A): 174,202 @ $0 · Grant/award (A): 226,885 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | McLoughlin Sean — Chief Operating Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2023-12-18 | 4 | Borkowski Astrid — Chief Medical Officer | Sale (S): 10,000 @ $15.50 | EDGAR |
Recent 8-K events — HilleVax, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-09-17 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-25 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-05-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-05 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-11-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-10-16 | 8-K | ? | EDGAR |
| 2024-08-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=HLVX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →